gefitinib has been researched along with glucosamine in 3 studies
Studies (gefitinib) | Trials (gefitinib) | Recent Studies (post-2010) (gefitinib) | Studies (glucosamine) | Trials (glucosamine) | Recent Studies (post-2010) (glucosamine) |
---|---|---|---|---|---|
5,231 | 566 | 2,919 | 10,273 | 280 | 1,467 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (66.67) | 24.3611 |
2020's | 1 (33.33) | 2.80 |
Authors | Studies |
---|---|
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Ekins, S; Williams, AJ; Xu, JJ | 1 |
Mirian, M; Rostami, M; Satari, N; Taymouri, S; Varshosaz, J | 1 |
3 other study(ies) available for gefitinib and glucosamine
Article | Year |
---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Preparation and evaluation of inhalable dry powder containing glucosamine-conjugated gefitinib SLNs for lung cancer therapy.
Topics: Administration, Inhalation; Dry Powder Inhalers; Gefitinib; Glucosamine; Humans; Lung Neoplasms; Nanoparticles; Particle Size; Powders | 2020 |